Investor Presentaiton slide image

Investor Presentaiton

Major R&D Pipeline: Alpha As of Jul 2022 Daiichi-Sankyo DS-7300 (JP/US) B7-H3-directed ADC ESCC, CRPC, squamous NSCLC, etc. DS-6000 (US) CDH6-directed ADC Renal cell carcinoma, ovarian cancer DS-1055 (JP/US) Anti-GARP antibody Solid tumors DS-1211 (US) TNAP inhibitor Pseudoxanthoma elasticum DS-6016 (JP) Anti-ALK2 antibody FOP DS-7011 (US) Anti-TLR7 antibody Systemic lupus erythematosus DS-2325 (US) KLK5 inhibitor Netherton syndrome Oncology Specialty medicine Vaccine Phase 1 PLX2853 (US) BET inhibitor AML PLX2853 (US) BET inhibitor Solid tumor Phase 2 Valemetostat (DS-3201) (JP/US/EU/Asia) EZH1/2 inhibitor PTCL DS-1001 (JP) Phase 3 Filed Valemetostat (DS-3201) (JP) EZH1/2 inhibitor Pexidartinib (JP/Asia) CSF-1/KIT/FLT3 inhibitor Tenosynovial giant cell tumor ATL/L Quizartinib (JP/US/EU/Asia) PLX2853 (US) BET inhibitor Gynecologic neoplasms, ovarian cancer PLX2853 (US) Valemetostat (DS-3201) (EU) EZH1/2 inhibitor BCL Mutant IDH1 inhibitor. Glioma DS-7300 (JP/US/EU/Asia) B7-H3-directed ADC ES-SCLC DS-5141 (JP) ENA oligonucleotide DMD DS-5670 (JP) COVID-19 mRNA vaccine COVID-19 (initial vaccination) FLT3 inhibitor AML 1L Esaxerenone (JP) MR blocker Diabetic nephropathy VN-0102/JVC-001 (JP) Measles mumps rubella combined vaccine DS-5670 (JP) COVID-19 mRNA vaccine COVID-19 (booster vaccination) BET inhibitor Prostate cancer DS-1594 (US) Menin-MLL binding inhibitor AML, ALL DS-9606 (US/EU) Target undisclosed ADC Solid tumors VN-0200 (JP) RS virus vaccine RS virus infection project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials SAKIGAKE Designation (JP) Orphan drug designation (JP/US/EU) VN-0107/MEDI3250 (JP) Live attenuated influenza vaccine nasal spray ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, BCL: B cell lymphoma, CRPC: castration-resistant prostate cancer, DMD: Duchenne muscular dystrophy, ESCC: esophageal squamous cell carcinoma, FOP: Fibrodysplasia ossificans progressive, LBCL: large B cell lymphoma, NSCLC: non small cell lung cancer, ES-SCLC: extensive stage-small cell lung cancer, PTCL: peripheral T-cell lymphoma 42
View entire presentation